Budd-Chiari syndrome secondary prevention: Difference between revisions
Jump to navigation
Jump to search
Mazia Fatima (talk | contribs) |
Mazia Fatima (talk | contribs) |
||
Line 11: | Line 11: | ||
*Anticoagulation should be initiated immediately in patients to prevent propagation of the clot, provided there are no contraindications. | *Anticoagulation should be initiated immediately in patients to prevent propagation of the clot, provided there are no contraindications. | ||
*Effective management of esophageal varices. | *Effective management of esophageal varices. | ||
*Patients with Budd-Chiari syndrome treated with balloon dilatation or stents require follow-up catheterizations and repeat dilatations or stent replacement. | |||
*All patients should have routine surveillance for hepatocellular carcinoma (HCC). | |||
==References== | ==References== |
Revision as of 20:24, 9 November 2017
Budd-Chiari syndrome Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Budd-Chiari syndrome secondary prevention On the Web |
American Roentgen Ray Society Images of Budd-Chiari syndrome secondary prevention |
Risk calculators and risk factors for Budd-Chiari syndrome secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.
Overview
Secondary Prevention
Secondary prevention strategies following Budd-Chiari syndrome include:
- Anticoagulation should be initiated immediately in patients to prevent propagation of the clot, provided there are no contraindications.
- Effective management of esophageal varices.
- Patients with Budd-Chiari syndrome treated with balloon dilatation or stents require follow-up catheterizations and repeat dilatations or stent replacement.
- All patients should have routine surveillance for hepatocellular carcinoma (HCC).